• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2014 Fiscal Year Final Research Report

Establishment of the biomarker in urothelial cancer patients treated with systemic combination chemotherapy.

Research Project

  • PDF
Project/Area Number 24592407
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Urology
Research InstitutionWakayama Medical University

Principal Investigator

MATSUMURA Nagahide  和歌山県立医科大学, 医学部, 講師 (30316103)

Co-Investigator(Renkei-kenkyūsha) HARA Isao  和歌山県立医科大学, 医学部, 教授 (10263378)
NAKAMURA Yasushi  和歌山県立医科大学, 医学部, 准教授 (60275352)
Project Period (FY) 2012-04-01 – 2015-03-31
Keywords尿路上皮癌」 / 膀胱癌 / バイオマーカー
Outline of Final Research Achievements

We recently demonstrated that high expression levels of human equilibrative nucleoside transporter 1 (hENT1), the major nucleoside transporter protein required for efficient uptake of gemcitabine into cytoplasm, was an independent prognostic marker as a positive regulator in patients with metastatic bladder cancer treated using gemcitabine-containing systemic chemotherapy. Ribonucleotide reductase 1 (RRM1) represents a mechanism of resistance to gemcitabine, and was shown in this study as a negative regulator response to gemcitabine-platinum chemotherapy. Our data demonstrated that high expression of RRM1 and low expression of hENT1 in tumor cells is associated with shorter survival in patients with metastatic bladder cancer treated using gemcitabine-containing chemotherapy. This outcome will lead to personalized medicine in urothelial cancer patients treated with systemic chemotherapy.

Free Research Field

尿路上皮癌

URL: 

Published: 2016-06-03  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi